Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters

被引:69
作者
Li, Xiao-Yang [1 ]
Zhao, Zhen-Xiong [1 ]
Huang, Min [1 ]
Feng, Ru [1 ]
He, Chi-Yu [1 ]
Ma, Chao [2 ]
Luo, Shi-Heng [2 ]
Fu, Jie [1 ]
Wen, Bao-Ying [1 ]
Ren, Long [1 ]
Shou, Jia-Wen [1 ]
Guo, Fang [1 ]
Chen, Yangchao [5 ]
Gao, Xin [4 ]
Wang, Yan [1 ]
Jiang, Jian-Dong [1 ,3 ]
机构
[1] Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Peking Union Med Coll, Beijing 100050, Peoples R China
[2] Shimadzu China Co Ltd, Beijing Analyt Applicat Ctr, Beijing 100020, Peoples R China
[3] Chinese Acad Med Sci, Inst Med Biotechnol, Peking Union Med Coll, Beijing 100050, Peoples R China
[4] Fudan Univ, Dept Endocrinol & Metab, Zhongshan Hosp, Shanghai 200032, Peoples R China
[5] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Shatin, Hong Kong, Peoples R China
基金
中国国家自然科学基金;
关键词
Berberine; Cholesterol; Hyperlipidemia; Mechanism; Excretion; Bile; LOWERING EFFICACY; IN-VITRO; RATS; COPROSTANOL; STATINS; MECHANISM; CELLS; COMBINATION; INHIBITION; ABSORPTION;
D O I
10.1186/s12967-015-0629-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Berberine (BBR), as a new medicine for hyperlipidemia, can reduce the blood lipids in patients. Mechanistic studies have shown that BBR activates the extracellular-signal regulated kinase pathway by stabilizing low-density-lipoprotein receptor mRNA. However, aside from inhibiting the intestinal absorption of cholesterol, the effects of BBR on other metabolic pathways of cholesterol have not been reported. This study aimed to investigate the action of BBR on the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. Methods: Golden hamsters were fed a high-fat diet (HFD) for 6 weeks to induce hyperlipidemia, followed by oral treatment with 50 and 100 mg/kg/day of BBR or 10 and 30 mg/kg/day of lovastatin for 10 days, respectively. The levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), transaminases, and total bile acid in the serum, liver, bile and feces were measured using an enzyme-linked immunosorbent assay. The cholesterol (as well as coprostanol) levels in the liver, bile and feces were determined by gas chromatography-mass spectrometry. Results: The HFD hamsters showed significantly hyperlipidemic characteristics compared with the normal hamsters. Treatment with BBR for 10 days reduced the serum TC, TG and LDL-C levels in HFD hamsters by 44-70, 34-51 and 47-71 %, respectively, and this effect was both dose-and time-dependent. Initially, a large amount of cholesterol accumulated in the hyperlipidemic hamster livers. After BBR treatment, reductions in the liver cholesterol were observed by day 3 and became significant by day 7 at both doses (P < 0.001). Meanwhile, bile cholesterol was elevated by day 3 and significantly increased at day 10 (P < 0.001). BBR promoted cholesterol excretion from the liver into the bile in hyperlipidemic hamsters but not in normal hamsters, and these results provide a link between the cholesterol-lowering effect of BBR with cholesterol excretion into the bile. Conclusions: We conclude that BBR significantly promoted the excretion of cholesterol from the liver to the bile in hyperlipidemic hamsters, which led to large decreases in the serum TC, TG and LDL-C levels. Additionally, compared with lovastatin, the BBR treatment produced no obvious side effects on the liver function.
引用
收藏
页数:9
相关论文
共 34 条
[1]   A Review on the Use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis [J].
Abdul-Majeed, Saif ;
Mohamed, Norazlina ;
Soelaiman, Ima-Nirwana .
CURRENT DRUG TARGETS, 2013, 14 (13) :1579-1590
[2]   Potent antiprotozoal activity of a novel semi-synthetic berberine derivative [J].
Bahar, Mark ;
Deng, Ye ;
Zhu, Xiaohua ;
He, Shanshan ;
Pandharkar, Trupti ;
Drew, Mark E. ;
Navarro-Vazquez, Armando ;
Anklin, Clemens ;
Gil, Roberto R. ;
Doskotch, Raymond W. ;
Werbovetz, Karl A. ;
Kinghorn, A. Douglas .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (09) :2606-2610
[3]   Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine [J].
Brusq, Jean-Marie ;
Ancellin, Nicolas ;
Grondin, Pascal ;
Guillard, Raphaelle ;
Martin, Sandrine ;
Saintillan, Yannick ;
Issandou, Marc .
JOURNAL OF LIPID RESEARCH, 2006, 47 (06) :1281-1288
[4]   Berberine decreases PCSK9 expression in HepG2 cells [J].
Cameron, Jamie ;
Ranheim, Trine ;
Kulseth, Mari Ann ;
Leren, Trond P. ;
Berge, Knut Erik .
ATHEROSCLEROSIS, 2008, 201 (02) :266-273
[5]   Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials (Publication with Expression of Concern. See vol. 13, pg. 177, 2018) [J].
Derosa, Giuseppe ;
Maffioli, Pamela ;
Cicero, Arrigo F. G. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (08) :1113-1124
[6]   Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats [J].
Dong, Shi-Fen ;
Hong, Ying ;
Liu, Ming ;
Hao, Ying-Zhi ;
Yu, Hai-Shi ;
Liu, Yang ;
Sun, Jian-Ning .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 660 (2-3) :368-374
[7]   Berberine and Itraconazole Are not Synergistic in Vitro against Aspergillus fumigatus Isolated from Clinical Patients [J].
Gao Lei ;
He Dan ;
Liu Jinhua ;
Yan Wei ;
Gao Song ;
Wang Li .
MOLECULES, 2011, 16 (11) :9218-9233
[8]   Gnotobiotic rats harboring human intestinal microbiota as a model for studying cholesterol-to-coprostanol conversion [J].
Gérard, P ;
Béguet, F ;
Lepercq, P ;
Rigottier-Gois, L ;
Rochet, V ;
Andrieux, C ;
Juste, C .
FEMS MICROBIOLOGY ECOLOGY, 2004, 47 (03) :337-343
[9]  
[何明坤 He Mingkun], 2004, [中国医院药学杂志, Chinese Journal of Hospital Pharmacy], V24, P389
[10]   Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy [J].
Hong, Y ;
Hui, SSC ;
Chan, BTY ;
Hou, JY .
LIFE SCIENCES, 2003, 72 (22) :2499-2507